1. European Urology Oncology
Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery 
Umberto Capitanio, Andrea Necchi, Alessandro Larcher, Francesco De Cobelli, Francesco Montorsi 
European Urology Oncology 
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Kaplan Meier estimates of oncological outcomes for 303 patients with nonmetastatic (cM0) renal cell carcinoma treated with surgery at San Raffaele Hospital and fulfilling the S-TRAC trial inclusion criteria [1]. (A) Metastatic progression after surgery stratified according to the presence of intermediate-risk (pT3a G1–3 pN0 M0) versus high-risk (pT3bc–4 and/or G4 and/or pN1) disease. (B) Overall survival after surgery for patients experiencing early metastatic progression (<6 mo) versus late metastatic progression (>6 mo) versus no clinical progression after nephrectomy. CE=cumulative events; NR=number at risk.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions